SUN K706

Drug Profile

SUN K706

Alternative Names: K0706; SUN K706; SUN-K0706

Latest Information Update: 23 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sun Pharma Advanced Research Company
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic myeloid leukaemia
  • Preclinical Parkinson's disease

Most Recent Events

  • 19 Nov 2016 Sun Pharma Advanced Research Company plans a phase II trial for Parkinson's disease in USA (PO) (NCT02970019)
  • 18 Nov 2016 Preclinical trials in Parkinson's disease in India (PO) before November 2016
  • 01 Mar 2016 Phase-I/II clinical trials in Chronic myeloid leukaemia (In volunteers) in USA (PO) (NCT02629692)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top